Equity Details
Price & Market Data
Price: $1.14
Daily Change: +$0.0313 / 2.74%
Daily Range: $1.04 - $1.18
Market Cap: $29,640,504
Daily Volume: 254,574
Performance Metrics
1 Week: 0.83%
1 Month: -14.25%
3 Months: -28.36%
6 Months: -59.82%
1 Year: -7.71%
YTD: -48.87%
About ABVC BioPharma, Inc. (ABVC)
Get a comprehensive snapshot of ABVC BioPharma, Inc. (ABVC). Current price: 1.14, daily change: +$0.0313 / 2.74%. Market cap: 29,640,504. Performance YTD, 1-week, and 3-month.
Company Details
Employees: 19
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
